Literature DB >> 28322979

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus.

Mercedes Pérez-Hernández1, María Encarnación Fernández-Valle2, Ana Rubio-Araiz1, Rebeca Vidal1, María Dolores Gutiérrez-López1, Esther O'Shea3, María Isabel Colado4.   

Abstract

The recreational drug of abuse, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier (BBB) integrity in rats through an early P2X7 receptor-mediated event which induces MMP-9 activity. Increased BBB permeability often causes plasma proteins and water to access cerebral tissue leading to vasogenic edema formation. The current study was performed to examine the effect of a single neurotoxic dose of MDMA (12.5 mg/kg, i.p.) on in vivo edema development associated with changes in the expression of the perivascular astrocytic water channel, AQP4, as well as in the expression of the tight-junction (TJ) protein, claudin-5 and Evans Blue dye extravasation in the hippocampus of adult male Dark Agouti rats. We also evaluated the ability of the MMP-9 inhibitor, SB-3CT (25 mg/kg, i.p.), to prevent these changes in order to validate the involvement of MMP-9 activation in MDMA-induced BBB disruption. The results show that MDMA produces edema of short duration temporally associated with changes in AQP4 expression and a reduction in claudin-5 expression, changes which are prevented by SB-3CT. In addition, MDMA induces a short-term increase in both tPA activity and expression, a serine-protease which is involved in BBB disruption and upregulation of MMP-9 expression. In conclusion, this study provides evidence enough to conclude that MDMA induces edema of short duration due to BBB disruption mediated by MMP-9 activation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AQP4; Blood-brain barrier; Edema; Evans Blue dye (PubChem CID: 24832074); MDMA; MDMA hydrochloride (PubChem CID: 71285); MMP-9; SB-3CT; SB-3CT (PubChem CID: 9883002)

Mesh:

Substances:

Year:  2017        PMID: 28322979     DOI: 10.1016/j.neuropharm.2017.03.019

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Therapeutic Target and Cell-signal Communication of Chlorpromazine and Promethazine in Attenuating Blood-Brain Barrier Disruption after Ischemic Stroke.

Authors:  Fengwu Li; Xiaokun Geng; James Yip; Yuchuan Ding
Journal:  Cell Transplant       Date:  2018-12-20       Impact factor: 4.064

2.  Neuroinflammatory Reactions in the Brain of 1,2-DCE-Intoxicated Mice during Brain Edema.

Authors:  Xiaoxia Jin; Tong Wang; Yingjun Liao; Jingjing Guo; Gaoyang Wang; Fenghong Zhao; Yaping Jin
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

3.  The Effects of Folic Acid on Testicular Histology, Sperm Quality, and Spermatogenesis Indices Following 3,4-Methylenedioxymethamphetamine Exposure in Adult Male Rats.

Authors:  Iman Rad; Arezoo Saberi; Najmeh Sadat Koochakzadeh-Nematollahi; Victoria Habibzadeh; Ehsan Salarkia; Sedigheh Amanollahi; Saeideh Nikpour
Journal:  Addict Health       Date:  2021-01

4.  Microglial Activation Damages Dopaminergic Neurons through MMP-2/-9-Mediated Increase of Blood-Brain Barrier Permeability in a Parkinson's Disease Mouse Model.

Authors:  Zhengzheng Ruan; Dongdong Zhang; Ruixue Huang; Wei Sun; Liyan Hou; Jie Zhao; Qingshan Wang
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

5.  Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting neuron apoptosis and MMP2/9 expression.

Authors:  Guoyong Zeng; Weijiang Ding; Yin Li; Meiying Sun; Liying Deng
Journal:  Exp Ther Med       Date:  2018-07-17       Impact factor: 2.447

Review 6.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.